





The protein p53 regulates the fate of cells [1].   
Blagosklonny and his colleagues [2], and others [3] in a 
series of studies have been using the non-genotoxic p53 
activator, Nutlin-3a, to understand further how p53 
induction can determine whether cells arrest die or 
senesce. In earlier work the p53 dependence of cell 
cycle arrest, apoptosis, autophagy and senescence has 
been un-equivocally demonstrated both in whole animal 
and tissue culture models. In these studies however p53 
induction was usually achieved by treatment with a 
DNA damaging drug or ionizing radiation and the 
question arises as to how much of the cell fate decision 
is mediated directly by p53 induction and how much by 
the fact that p53 is being induced in the environment of 
a “damaged” cell. Indeed when genetic “reactivation “ 
of p53 is induced in lymphoma models [4] apoptosis is 
the mechanism of tumor elimination, while in a liver 
tumor model, p53 induced senescence and macrophage 
engulfment is the route to regression [5]. In these 
models however the cells are tumor cells, so p53 
induction is still taking place in a “damaged or stressed” 
cell environment. Now using Nutlin-3a alone at varying 
doses in normal cells Leontieva et al [6] showed that the 
response to p53 is very sensitive indeed to the level and 
duration of the p53 response. This seems to be due to 
the ability of high levels of p53 to induce both cell cycle 
arrest and inhibition of the mTOR pathway, while at 
lower doses, p21 is induced but mTOR inhibition is not. 
Simply put the inhibition of the cell cycle without mTOR 
inhibition leads to senescence while dual inhibition       
leads to a reversible quiescence. This can then lead                 
to  the  counter-intuitive  observation  that  cells  recover           
better from high doses than from low doses of Nutlin-3a 
In addition holding cells in a quiescent state for too                 





















duration of the p53 signal are critical for outcome. 
These studies are beginning to throw important light on 
critical issues of the response of both normal and 
tumour tissue to therapy. Indeed Leontieva et al showed 
that Doxorubicin used at the wrong dose/duration might 
induce a reversible quiescence rather than the desired 
irreversible senescence or apoptosis in p53 wild type 
tumor cells. This could help to explain earlier 
observations by de The and group [7,8] that women 
with advanced breast cancer show a better response to 
DNA damaging chemotherapy when they have mutant 
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